Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast

Breast Cancer Research and Treatment

Volumn 161, Issue 1, 2017, Pages 17-28

  Campbell, Michael J ^a   Baehner, Frederick ^a   O’Meara, Tess ^b   Ojukwu, Ekene ^b   Han, Booyeon ^b   Mukhtar, Rita ^a   Tandon, Vickram ^b   Endicott, Max ^b   Zhu, Zelos ^b   Wong, Jasmine ^a   Krings, Gregor ^a   Au, Alfred ^a   Gray, Joe W ^c   Esserman, Laura ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Breast; DCIS; Immune microenvironment

Indexed keywords

CD20 ANTIGEN; CD68 ANTIGEN; CYCLINE; HLA DR ANTIGEN; TAMOXIFEN; TRANSCRIPTION FACTOR FOXP3; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; INTRADUCTAL CARCINOMA; LUMPECTOMY; MACROPHAGE; MAJOR CLINICAL STUDY; MASTECTOMY; METASTASIS; PREDICTION; PRIORITY JOURNAL; RECURRENCE RISK; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; BREAST TUMOR; CANCER GRADING; CANCER STAGING; IMMUNOLOGY; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; METABOLISM; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PATHOLOGY; PROGNOSIS; TUMOR RECURRENCE; TUMOR VOLUME;

ADULT; AGED; BIOMARKERS; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LYMPHOCYTE COUNT; LYMPHOCYTE SUBSETS; LYMPHOCYTES, TUMOR-INFILTRATING; MACROPHAGES; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PATIENT OUTCOME ASSESSMENT; PROGNOSIS; TUMOR BURDEN; TUMOR MICROENVIRONMENT;

EID: 84992406238     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-016-4036-0     Document Type: Article

References (38)

1. Siziopikou KP (2013) Ductal carcinoma in situ of the breast: current concepts and future directions. Arch Pathol Lab Med 137(4):462–466. doi:10.5858/arpa.2012-0078-RA
2. Bianchi S, Vezzosi V (2008) Microinvasive carcinoma of the breast. Pathol Oncol Res 14(2):105–111. doi:10.1007/s12253-008-9054-8
3. Rosner D, Lane WW, Penetrante R (1991) Ductal carcinoma in situ with microinvasion. A curable entity using surgery alone without need for adjuvant therapy. Cancer 67(6):1498–1503
4. Solin LJ, Fowble BL, Yeh IT, Kowalyshyn MJ, Schultz DJ, Weiss MC, Goodman RL (1992) Microinvasive ductal carcinoma of the breast treated with breast-conserving surgery and definitive irradiation. Int J Radiat Oncol Biol Phys 23(5):961–968
5. Esserman L, Yau C (2015) Rethinking the standard for ductal carcinoma in situ treatment. JAMA Oncol 1(7):881–883. doi:10.1001/jamaoncol.2015.2607
6. Narod SA, Iqbal J, Giannakeas V, Sopik V, Sun P (2015) Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncol 1(7):888–896. doi:10.1001/jamaoncol.2015.2510
7. Bijker N, Meijnen P, Peterse JL, Bogaerts J, Van Hoorebeeck I, Julien JP, Gennaro M, Rouanet P, Avril A, Fentiman IS, Bartelink H, Rutgers EJ (2006) Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853—a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 24(21):3381–3387. doi:10.1200/JCO.2006.06.1366
8. Bijker N, Peterse JL, Duchateau L, Julien JP, Fentiman IS, Duval C, Di Palma S, Simony-Lafontaine J, de Mascarel I, van de Vijver MJ (2001) Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol 19(8):2263–2271
9. Fisher B, Dignam J, Wolmark N, Mamounas E, Costantino J, Poller W, Fisher ER, Wickerham DL, Deutsch M, Margolese R, Dimitrov N, Kavanah M (1998) Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 16(2):441–452
10. Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N (2001) Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol 28(4):400–418
11. Holmberg L, Garmo H, Granstrand B, Ringberg A, Arnesson LG, Sandelin K, Karlsson P, Anderson H, Emdin S (2008) Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast. J Clin Oncol 26(8):1247–1252. doi:10.1200/JCO.2007.12.7969
12. Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M (2003) Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 362(9378):95–102
13. Esserman LJ, Kumar AS, Herrera AF, Leung J, Au A, Chen YY, Moore DH, Chen DF, Hellawell J, Wolverton D, Hwang ES, Hylton NM (2006) Magnetic resonance imaging captures the biology of ductal carcinoma in situ. J Clin Oncol 24(28):4603–4610. doi:10.1200/JCO.2005.04.5518
14. Wai ES, Lesperance ML, Alexander CS, Truong PT, Moccia P, Culp M, Lindquist J, Olivotto IA (2011) Predictors of local recurrence in a population-based cohort of women with ductal carcinoma in situ treated with breast conserving surgery alone. Ann Surg Oncol 18(1):119–124. doi:10.1245/s10434-010-1214-x
15. Kurniawan ED, Rose A, Mou A, Buchanan M, Collins JP, Wong MH, Miller JA, Mann GB (2010) Risk factors for invasive breast cancer when core needle biopsy shows ductal carcinoma in situ. Arch Surg 145(11):1098–1104. doi:10.1001/archsurg.2010.243
16. Silverstein MJ (2003) The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast. Am J Surg 186(4):337–343
17. Silverstein MJ, Lagios MD (2015) Treatment selection for patients with ductal carcinoma in situ (DCIS) of the breast using the University of Southern California/Van Nuys (USC/VNPI) prognostic index. Breast J 21(2):127–132. doi:10.1111/tbj.12368
18. Adams S, Goldstein LJ, Sparano JA, Demaria S, Badve SS (2015) Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC). Oncoimmunology 4(9):e985930. doi:10.4161/2162402X.2014.985930
19. Campbell MJ, Tonlaar NY, Garwood ER, Huo D, Moore DH, Khramtsov AI, Au A, Baehner F, Chen Y, Malaka DO, Lin A, Adeyanju OO, Li S, Gong C, McGrath M, Olopade OI, Esserman LJ (2011) Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res Treat 128(3):703–711. doi:10.1007/s10549-010-1154-y
20. de la Cruz-Merino L, Barco-Sanchez A, Henao Carrasco F, Nogales Fernandez E, Vallejo Benitez A, Brugal Molina J, Martinez Peinado A, Grueso Lopez A, Ruiz Borrego M, Manuel Codes, de Villena M, Sanchez-Margalet V, Nieto-Garcia A, Alba Conejo E, Casares Lagar N, Ibanez Martinez J (2013) New insights into the role of the immune microenvironment in breast carcinoma. Clin Dev Immunol 2013:785317. doi:10.1155/2013/785317
21. Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, Ravoet M, Le Buanec H, Sibille C, Manfouo-Foutsop G, Veys I, Haibe-Kains B, Singhal SK, Michiels S, Rothe F, Salgado R, Duvillier H, Ignatiadis M, Desmedt C, Bron D, Larsimont D, Piccart M, Sotiriou C, Willard-Gallo K (2013) CD4(+) follicular helper T cell infiltration predicts breast cancer survival. J Clin Investig 123(7):2873–2892. doi:10.1172/JCI67428
22. Ibrahim EM, Al-Foheidi ME, Al-Mansour MM, Kazkaz GA (2014) The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis. Breast Cancer Res Treat 148(3):467–476. doi:10.1007/s10549-014-3185-2
23. + tumor infiltrating lymphocytes in patients with breast cancer: a meta-analysis. BMC Cancer 15(1):727. doi:10.1186/s12885-015-1742-7
24. Lee HJ, Park IA, Song IH, Shin SJ, Kim JY, Yu JH, Gong G (2015) Tertiary lymphoid structures: prognostic significance and relationship with tumour-infiltrating lymphocytes in triple-negative breast cancer. J Clin Pathol 69(5):422–430. doi:10.1136/jclinpath-2015-203089
25. Matsumoto H, Koo SL, Dent R, Tan PH, Iqbal J (2015) Role of inflammatory infiltrates in triple negative breast cancer. J Clin Pathol 68(7):506–510. doi:10.1136/jclinpath-2015-202944
26. + lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study. Breast Cancer Res 17(1):124. doi:10.1186/s13058-015-0632-x
27. Mukhtar RA, Nseyo O, Campbell MJ, Esserman LJ (2011) Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics. Expert Rev Mol Diagn 11(1):91–100. doi:10.1586/erm.10.97
28. Obeid E, Nanda R, Fu YX, Olopade OI (2013) The role of tumor-associated macrophages in breast cancer progression (review). Int J Oncol 43(1):5–12. doi:10.3892/ijo.2013.1938
29. Watanabe MA, Oda JM, Amarante MK, Cesar Voltarelli J (2010) Regulatory T cells and breast cancer: implications for immunopathogenesis. Cancer Metastasis Rev 29(4):569–579. doi:10.1007/s10555-010-9247-y
30. Lee AH, Happerfield LC, Bobrow LG, Millis RR (1997) Angiogenesis and inflammation in ductal carcinoma in situ of the breast. J Pathol 181(2):200–206. doi:10.1002/(SICI)1096-9896(199702)181:2<200:AID-PATH726>3.0.CO;2-K
31. Ramachandra S, Machin L, Ashley S, Monaghan P, Gusterson BA (1990) Immunohistochemical distribution of c-erbB-2 in in situ breast carcinoma–a detailed morphological analysis. J Pathol 161(1):7–14. doi:10.1002/path.1711610104
32. Lal A, Chan L, Devries S, Chin K, Scott GK, Benz CC, Chen YY, Waldman FM, Hwang ES (2013) FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast. Breast Cancer Res Treat 139(2):381–390. doi:10.1007/s10549-013-2556-4
33. Sharma M, Beck AH, Webster JA, Espinosa I, Montgomery K, Varma S, van de Rijn M, Jensen KC, West RB (2010) Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ. Breast Cancer Res Treat 123(2):397–404. doi:10.1007/s10549-009-0654-0
34. Carpenter AE, Jones TR, Lamprecht MR, Clarke C, Kang IH, Friman O, Guertin DA, Chang JH, Lindquist RA, Moffat J, Golland P, Sabatini DM (2006) Cell Profiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol 7(10):R100. doi:10.1186/gb-2006-7-10-r100
35. Kamentsky L, Jones TR, Fraser A, Bray MA, Logan DJ, Madden KL, Ljosa V, Rueden C, Eliceiri KW, Carpenter AE (2011) Improved structure, function and compatibility for cell profiler: modular high-throughput image analysis software. Bioinformatics 27(8):1179–1180. doi:10.1093/bioinformatics/btr095
36. Thompson E, Taube JM, Elwood H, Sharma R, Meeker A, Warzecha HN, Argani P, Cimino-Mathews A, Emens LA (2016) The immune microenvironment of breast ductal carcinoma in situ. Mod Pathol 29(3):249–258. doi:10.1038/modpathol.2015.158
37. Solin LJ, Gray R, Baehner FL, Butler SM, Hughes LL, Yoshizawa C, Cherbavaz DB, Shak S, Page DL, Sledge GW Jr, Davidson NE, Ingle JN, Perez EA, Wood WC, Sparano JA, Badve S (2013) A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst 105(10):701–710. doi:10.1093/jnci/djt067
38. Knopfelmacher A, Fox J, Lo Y, Shapiro N, Fineberg S (2015) Correlation of histopathologic features of ductal carcinoma in situ of the breast with the oncotype DX DCIS score. Mod Pathol 28(9):1167–1173. doi:10.1038/modpathol.2015.79